Publicacións en colaboración con investigadores/as de Hospital General de Castellón (5)

2024

  1. ERRATUM: Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs

    Endocrine-related cancer

  2. Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs

    Endocrine-Related Cancer, Vol. 31, Núm. 7

2023

  1. Experience with the ENDMAP project, a training activity for Family Doctors in Endocrinology and Nutrition

    Atencion Primaria Practica, Vol. 5, Núm. 4

  2. Magnetic resonance imaging as a predictor of therapeutic response to pasireotide in acromegaly

    Clinical Endocrinology, Vol. 99, Núm. 4, pp. 378-385

2022

  1. Prevention of Cardiorenal Complications with Sodium–Glucose Cotransporter Type 2 Inhibitors: A Narrative Review

    Diabetes Therapy, Vol. 13, pp. 5-17